Panacea Biotec Limited (NSE:PANACEABIO)

Panacea Biotec Financials Overview

Financials in millions INR. Fiscal year is April - March.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Revenue Revenue Growth	6,398	6,398	5,591	5,592	4,599	6,612
Revenue Growth	14.43%	14.43%	-0.01%	21.57%	-30.44%	5.83%
Gross Profit Gross Profit Growth	3,593	3,593	3,596	3,290	2,073	3,990
Operating Income Operating Income Growth	-377.2	-377.2	-529.78	-414.69	-1,027	-484.18
Net Income Net Income Growth	-53.7	-53.7	-83.7	-11.73	-332.37	10,783
Earnings Per Share EPS Growth	-0.88	-0.88	-1.37	-0.19	-5.43	176.05
EPS Growth	-	-	-	-	-	-

Revenue by Segment

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Vaccines Vaccines Growth	4,103	4,103	3,098	3,596	2,570	2,348
Formulations Formulations Growth	2,295	2,295	2,493	1,996	2,030	4,265
Total Total Growth	6,398	6,398	5,591	5,592	4,599	6,612

Cash & Debt

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Investments Cash & Investments Growth	744	744	1,294	1,514	2,130	5,516
Total Debt Total Debt Growth	236.6	236.6	222.06	209.94	202.19	341.55
Net Cash (Debt) Net Cash Growth	507.4	507.4	1,072	1,304	1,928	5,175
Net Cash Growth	-52.65%	-52.65%	-17.85%	-32.35%	-62.74%	-
Net Cash Per Share Net Cash Per Share Growth	8.31	8.31	17.50	21.30	31.48	84.48

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Operating Cash Flow Operating Cash Flow Growth	166.8	166.8	-273.69	34.68	-4,225	-1,084
Capital Expenditures CapEx Growth	-540.9	-540.9	-503.05	-828.76	-409.46	-125.1
Free Cash Flow Free Cash Flow Growth	-374.1	-374.1	-776.74	-794.08	-4,634	-1,210
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Gross Margin	56.16%	56.16%	64.31%	58.85%	45.07%	60.35%
Operating Margin	-5.90%	-5.90%	-9.48%	-7.42%	-22.34%	-7.32%
Pretax Margin	-1.15%	-1.15%	-1.42%	0.26%	2.78%	219.19%
Profit Margin	-0.84%	-0.84%	-1.50%	-0.21%	-7.23%	163.08%
FCF Margin	-5.85%	-5.85%	-13.89%	-14.20%	-100.75%	-18.29%

Valuation

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug 2, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
PE Ratio	-	-	-	-	-	0.84
PS Ratio	4.03	2.83	4.83	1.33	1.44	1.37

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 31, 2026

Data Sources Report a data error